INCR PRESS-RELEASE SEC Filing Analysis

Latest settled — T+20d

INCR ▲ +20.50% at T+20d

NEUTRAL call ✓ call won +20.50% · α vs SPY +15.21% · entry $0.8880 → $1.07

Next anchor: T+60d in 7w

Last close $0.9900 (close Jun 8) · +11.49% from $0.8880 entry

Entry anchored
Apr 30, 12:56 PM ET
via Databento tick

T+1d

-7.54%

call -7.54% · α -7.20%

$0.8210

settled 6w ago

T+5d

-5.29%

call -5.29% · α -7.64%

$0.8410

settled 5w ago

T+20d

+20.50%

call +20.50% · α +15.21%

$1.07

settled 12d ago

T+60d

—

call — · α —

—

in 7w

Price Chart

Loading chart...

Executive Summary

InterCure reported FY2025 revenue of NIS 270M (+13% YoY), a net loss of NIS 37M (improved from NIS 73M loss in 2024), and Adjusted EBITDA of NIS 47M (+90% YoY). The company generated positive operating cash flow of NIS 17M and resumed production at its Nir Oz facility, but the recovery timeline has extended and the company faces ongoing risks from war-related damages and Bazelet restructuring proceedings.

Actionable Insight

Revenue growth and cash flow improvement are positive, but the extended Nir Oz recovery timeline and Bazelet restructuring create uncertainty. Monitor progress on war compensation claims and Botanico acquisition closing for near-term catalysts. The CEO's insider buying and new activist shareholder suggest confidence in recovery trajectory.

Key Facts

FY2025 revenue of NIS 270M, up 13% YoY from NIS 239M
Net loss of NIS 37M, improved from NIS 73M loss in 2024
Adjusted EBITDA of NIS 47M, up 90% from NIS 24M in 2024
Positive operating cash flow of NIS 17M vs negative NIS 67M in 2024
Resumed production at Nir Oz facility, but recovery timeline extended
Received NIS 82M in war compensation advances against NIS 251M claim
CEO acquired over 500,000 shares; new 7% shareholder Yaron Jacobi
Entered agreement to acquire Botanico Ltd (ISHI) with expected revenues of NIS 30M in H2 2026
Acquired 28% stake in Cannasoul R&D with path to 51%
Cash on hand NIS 49M as of Dec 31, 2025, down from NIS 77M

Financial Impact

Revenue growth of 13% YoY to NIS 270M; Adjusted EBITDA nearly doubled to NIS 47M; net loss halved to NIS 37M

revenueadjusted_ebitdaoperating_cash_flownet_income

Risk Factors

Extended recovery timeline for Nir Oz facility beyond original plan
Bazelet restructuring proceedings and related legal developments
Dependence on war compensation from Israeli authorities (NIS 251M claim, only NIS 82M received)
Cash burn from NIS 77M to NIS 49M despite positive operating cash flow
Pending Botanico acquisition may not close or deliver expected revenues

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Analyst Consensus

86% bullish (7 analysts)

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3285596

2 reports for INCR

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for INCR — sortable, filterable
	Type				Now
Apr 30, 2026 5w ago	Press Release MIXED ★ 6/10	$0.8880 $1.07	▲ +20.50%	▲ +15.21%	$0.9900 (+11.49%)
Apr 30, 2026 5w ago	20-F BEARISH ★ 7/10	$0.8880 $1.07	▼ −20.50%	▼ −15.23%	$0.9900 (−11.49%)

US Market Status

Market Closed — Opens in 8h 35m

Related Tickers

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access